Company: BSX
Filing Date: 2025-02-24
Form Type: 424B2
Source: 0001104659-25-016521
Chunk: 17

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-24
Form: 424B2
Chunk 17
---
” in this prospectus supplement, AMS Europe will be required to offer to repurchase the notes upon the occurrence of a Change of Control Repurchase Event. There can be no assurance that we will have sufficient funds available at the time of any Change of Control Repurchase Event to be able to consummate a Change of Control Offer for all notes then outstanding at a purchase price for 101% of their principal amount thereof, plus accrued and unpaid interest to the Change of Control Payment Date. In addition, a change of control (as described herein under the heading “Description of the Notes — Repurchase at the Option of Holders Upon Change of Control Repurchase Event”) and certain other change of control events would constitute an event of default under certain of our credit agreements. As a result, we may not be able to make any of the required payments on, or repurchases of, the notes without obtaining the consent of the lenders under certain of our credit agreements or have the ability to arrange financing on acceptable terms.

The notes do not restrict our ability to incur additional debt or prohibit us from taking other actions that could negatively impact holders of the notes.

Neither we nor any of our subsidiaries, including AMS Europe, are restricted under the terms of the notes or the indenture governing the notes from incurring additional indebtedness. The terms of the indenture limit Boston Scientific’s and AMS Europe’s ability to merge or consolidate with another entity or transfer all or substantially all of the property and assets of Boston Scientific or AMS Europe, as applicable, and limit the ability of Boston Scientific and its Subsidiaries to create, grant or incur liens. However, these limitations are subject to numerous exceptions. See “Description of Debt Securities — Limitation on Liens” and “Description of Debt Securities — Merger, Consolidation, or Sale of Assets” in the accompanying prospectus. In addition, the notes do not require us to achieve or maintain any minimum financial results relating to our financial position or results of operations. Our ability to recapitalize, incur additional debt, secure existing or future debt, or take a number of other actions that are not limited by the terms of the indenture, the notes and the guarantees, including repurchasing indebtedness or capital stock, or paying dividends, could have the effect of diminishing AMS Europe’s ability to make payments on the notes when due.

Our financial performance and other factors could adversely impact AMS Europe’s ability to make payments on the notes.

AMS Europe’s ability to make scheduled payments with respect to the notes will depend on